These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. Brown E; Wilding JPH; Alam U; Barber TM; Karalliedde J; Cuthbertson DJ Ann Med; 2021 Dec; 53(1):2072-2089. PubMed ID: 33107349 [TBL] [Abstract][Full Text] [Related]
3. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Davies MJ; Drexel H; Jornayvaz FR; Pataky Z; Seferović PM; Wanner C Cardiovasc Diabetol; 2022 Aug; 21(1):144. PubMed ID: 35927730 [TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter 2 inhibitors and cardiovascular clinical outcomes in acute heart failure: A narrative review. Rodriguez R; Kaluzna SD Am J Health Syst Pharm; 2023 Jun; 80(13):818-826. PubMed ID: 36971375 [TBL] [Abstract][Full Text] [Related]
5. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes. Woo V; Connelly K; Lin P; McFarlane P Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677 [No Abstract] [Full Text] [Related]
6. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. Nassif ME; Kosiborod M Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589 [TBL] [Abstract][Full Text] [Related]
7. Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure. Chen K; Nie Z; Shi R; Yu D; Wang Q; Shao F; Wu G; Wu Z; Chen T; Li C JAMA Netw Open; 2023 Aug; 6(8):e2330754. PubMed ID: 37615988 [TBL] [Abstract][Full Text] [Related]
8. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease. Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940 [TBL] [Abstract][Full Text] [Related]
9. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure. Greene SJ; Butler J; Kosiborod MN Am J Med; 2024 Feb; 137(2S):S25-S34. PubMed ID: 38184323 [TBL] [Abstract][Full Text] [Related]
10. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science. Cruz JE; Ahuja T; Bridgeman MB Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393 [TBL] [Abstract][Full Text] [Related]
11. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. McGuire DK; Shih WJ; Cosentino F; Charbonnel B; Cherney DZI; Dagogo-Jack S; Pratley R; Greenberg M; Wang S; Huyck S; Gantz I; Terra SG; Masiukiewicz U; Cannon CP JAMA Cardiol; 2021 Feb; 6(2):148-158. PubMed ID: 33031522 [TBL] [Abstract][Full Text] [Related]
12. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. Lan NSR; Fegan PG; Yeap BB; Dwivedi G ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090 [TBL] [Abstract][Full Text] [Related]
13. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Giugliano D; Longo M; Scappaticcio L; Bellastella G; Maiorino MI; Esposito K Cardiovasc Diabetol; 2021 Dec; 20(1):236. PubMed ID: 34915880 [TBL] [Abstract][Full Text] [Related]